People: Targacept Inc (TRGT.O)

TRGT.O on Nasdaq

2.56USD
17 Sep 2014
Price Change (% chg)

$0.06 (+2.40%)
Prev Close
$2.50
Open
$2.52
Day's High
$2.59
Day's Low
$2.50
Volume
63,486
Avg. Vol
301,346
52-wk High
$6.11
52-wk Low
$2.49

Search Stocks

Richard, John 

Brief Biography

Mr. John P. Richard is the Non-Executive Independent Chairman of the Board of Targacept, Inc. Mr. Richard has significant corporate, operational and transactional life sciences experience, having served in various executive, director and advisory roles throughout his career. He currently is a partner and director of two life science focused investment firms, Phase4 Partners and Georgia Venture Partners. In addition, John is a board member of Biota Pharmaceuticals (NASDAQ: BOTA) and Zosano Pharma and serves as an advisor to Albireo AB and Nabriva Therapeutics AG. Earlier in his career, he was Executive Vice President, Business Development at SEQUUS Pharmaceuticals, Inc., where he was responsible for negotiating the acquisition of SEQUUS by ALZA Corporation. Prior to joining SEQUUS, John headed business development for VIVUS, Inc. and Genome Therapeutics Corporation, where he was responsible for establishing numerous pharmaceutical alliances. He was also the CEO and co-founder of Impath Inc., which became part of Genzyme. John received his M.B.A. from Harvard Business School and his B.S. from Stanford University.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

John Richard

--

Stephen Hill

699,368

Alan Musso

715,717

Patrick Rock

--

David Hosford

549,291

Steven Toler

--
As Of 30 Dec 2013
Search Stocks